Actinogen’s recent quarterly update confirmed that the company remains on track to start US recruitment in H1 CY23 for its six-month, placebo-controlled Phase IIb portion of the XanaMIA study. The study is designed to assess the safety and efficacy of Xanamem in a population of patients with mild cognitive impairment (CI) and mild Alzheimer’s disease (AD), who at baseline will have been confirmed as biomarker-positive for AD (as determined through elevated blood phosphorylated Tau, or pTau). The ....
06 Feb 2023
Actinogen Medical - On track to start Phase IIb XanaMIA study
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Actinogen Medical - On track to start Phase IIb XanaMIA study
Actinogen Medical Limited (ACW:ASX) | 0 0 -9.4% | Mkt Cap: 35.9m
- Published:
06 Feb 2023 -
Author:
Pooya Hemami -
Pages:
2
Actinogen’s recent quarterly update confirmed that the company remains on track to start US recruitment in H1 CY23 for its six-month, placebo-controlled Phase IIb portion of the XanaMIA study. The study is designed to assess the safety and efficacy of Xanamem in a population of patients with mild cognitive impairment (CI) and mild Alzheimer’s disease (AD), who at baseline will have been confirmed as biomarker-positive for AD (as determined through elevated blood phosphorylated Tau, or pTau). The ....